Freenome

Early cancer detection through AI and multiomics technology

Freenome provides early cancer detection services using artificial intelligence and multiomics technology. This enables the detection of cancer in its earliest stages, making it more treatable. The company's platform combines science and ease to provide a standard blood draw test. Freenome's research programs drive discovery, development, and validation of its early cancer detection tests. By utilizing a rigorous clinical program, the company pushes for what's possible in early cancer detection. This approach has the potential to make a real dent in ending cancer. The company brings together passionate creators and ambitious builders to achieve this goal.